Page last updated: 2024-08-24

ibandronic acid and Low Bone Density

ibandronic acid has been researched along with Low Bone Density in 21 studies

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (4.76)18.2507
2000's7 (33.33)29.6817
2010's10 (47.62)24.3611
2020's3 (14.29)2.80

Authors

AuthorsStudies
Ishimoto, T; Matsumoto, Y; Nakano, T; Ozasa, R; Saito, M1
Ishimoto, T; Matsugaki, A; Matsumoto, Y; Nakano, T; Ozasa, R; Saito, M1
Abualhamael, SA; Baig, M; Malik, AA; Shahzad, M; Tariq, S1
Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L1
Adamidou, F; Anagnostis, P; Charizopoulou, M; Garipidou, V; Goulis, DG; Karagiannis, A; Karras, S; Vakalopoulou, S; Vyzantiadis, TA1
Mészaros, Á; Veszelyné Kotán, E1
Baek, HJ; Choe, JY; Kang, SW; Lee, SG; Lee, YJ; Park, SH; Park, W; Park, YB; Shin, K; Song, JS; Song, YW; Yoo, B; Yoo, DH; Yoo, WH1
Bachmann, G; Bonnick, SL; Civitelli, R; Kohles, JD; Martens, M; Silverman, S; Tanner, SB1
Mattos, K; Migliorati, CA; Palazzolo, MJ1
Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF1
Armbrecht, G; Beller, G; Bock, O; Börst, H; Degner, C; Felsenberg, D; Martus, P; Roth, HJ1
Chapurlat, RD; de Vernejoul, MC; Delmas, PD; Laroche, M; Rouanet, S; Thomas, T1
Lo, JC; O'Ryan, FS1
Hommann, M; Kaemmerer, D; Lehmann, G; Schmidt, B; Settmacher, U; Wolf, G1
Dobrokhotov, IV; Durnova, GN; Il'ina-Kakueva, EI; Kaplanskiĭ, AS; Larina, IM; Morukov, BV1
Bauss, F; Eberhardt, C; Kurth, AH; Müller, S; Schwarz, M; Steinacker, M1
Lipton, A1
De Broe, M; Ketteler, M; Persy, V1
Barrett, J; Gieschke, R; Goggin, T; Pillai, G; Steimer, JL; Worth, E1
Baumann, M; Christensen, JO; Clemmesen, B; Ravn, P1

Reviews

2 review(s) available for ibandronic acid and Low Bone Density

ArticleYear
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
    Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1

    Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid

2016
New therapeutic agents for the treatment of bone diseases.
    Expert opinion on biological therapy, 2005, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid

2005

Trials

7 trial(s) available for ibandronic acid and Low Bone Density

ArticleYear
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 108

    Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method

2019
The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:2

    Topics: Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Hemophilia A; Hemophilia B; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors

2013
Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.
    Clinical therapeutics, 2017, Volume: 39, Issue:2

    Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Bone Diseases, Metabolic; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Peptides

2017
Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
    Bone, 2012, Volume: 50, Issue:1

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; X-Ray Microtomography

2012
Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:1

    Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Radius; Tibia; Tomography, X-Ray Computed

2013
Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
    International journal of clinical pharmacology and therapeutics, 2006, Volume: 44, Issue:12

    Topics: Adult; Aged; Area Under Curve; Asian People; Body Weight; Bone Density Conservation Agents; Bone Diseases, Metabolic; Collagen Type I; Creatinine; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Peptides; Postmenopause; Retrospective Studies; Sex Factors; Tissue Distribution; White People

2006
Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
    Bone, 1998, Volume: 22, Issue:5

    Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Femur; Follow-Up Studies; Forearm; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Peptides; Spine

1998

Other Studies

12 other study(ies) available for ibandronic acid and Low Bone Density

ArticleYear
Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae.
    Calcified tissue international, 2022, Volume: 110, Issue:6

    Topics: Animals; Apatites; Bone Density; Bone Diseases, Metabolic; Elastic Modulus; Endocrine System Diseases; Estrogens; Ibandronic Acid; Osteoporosis; Rats; Spine

2022
Combination treatment with ibandronate and eldecalcitol prevents osteoporotic bone loss and deterioration of bone quality characterized by nano-arrangement of the collagen/apatite in an ovariectomized aged rat model.
    Bone, 2022, Volume: 157

    Topics: Animals; Apatites; Bone Density; Bone Diseases, Metabolic; Collagen; Estrogens; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Vitamin D

2022
Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females.
    PloS one, 2023, Volume: 18, Issue:9

    Topics: Bone Diseases, Metabolic; Case-Control Studies; Female; Humans; Ibandronic Acid; Osteoprotegerin; Polymorphism, Single Nucleotide; Postmenopause

2023
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Journal of women's health (2002), 2009, Volume: 18, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Drug Administration Schedule; Drug Substitution; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Prospective Studies; Surveys and Questionnaires

2009
Pricey osteoporosis remedy doesn't beat older drugs.
    Consumer reports, 2009, Volume: 74, Issue:8

    Topics: Advertising; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Dietary; Diphosphonates; Drug Costs; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Vitamin D

2009
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
    Journal of the American Dental Association (1939), 2010, Volume: 141, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors

2010
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:2

    Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid

2012
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:8

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Cohort Studies; Debridement; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Ibandronic Acid; Male; Middle Aged; Osteolysis; Osteoporosis; Osteosclerosis; Retrospective Studies; Tooth Extraction; Treatment Outcome; Wound Healing

2012
Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.
    Transplantation proceedings, 2012, Volume: 44, Issue:5

    Topics: Absorptiometry, Photon; Administration, Oral; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chi-Square Distribution; Cholecalciferol; Creatinine; Dietary Supplements; Diphosphonates; Drug Administration Schedule; Femur Neck; Fractures, Bone; Germany; Humans; Ibandronic Acid; Liver Transplantation; Lumbar Vertebrae; Osteoporosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome

2012
[Effects of ibandronate on the osteopenia process in tail-suspended rats].
    Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine, 2003, Volume: 37, Issue:4

    Topics: Adrenal Glands; Animals; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Data Interpretation, Statistical; Diphosphonates; Hindlimb Suspension; Ibandronic Acid; Male; Rats; Thymus Gland; Tibia; Time Factors; Weightlessness

2003
The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.
    Bone, 2005, Volume: 37, Issue:2

    Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Durapatite; Female; Femur; Ibandronic Acid; Osseointegration; Osteoporosis; Ovariectomy; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Titanium

2005
Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?
    Kidney international, 2006, Volume: 70, Issue:9

    Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcinosis; Diphosphonates; Ibandronic Acid; Kidney; Kidney Failure, Chronic; Mice; Rats; Vascular Diseases

2006